2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsPredicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study
Adelman RA, Parnes AJ, Bopp S, Othman I, Ducournau D. Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study. BioMed Research International 2015, 2015: 870987. PMID: 25705695, PMCID: PMC4325227, DOI: 10.1155/2015/870987.Peer-Reviewed Original ResearchConceptsRetinal vein occlusionCentral retinal vein occlusionBranch retinal vein occlusionVein occlusionMacular edemaVisual acuityIntravitreal antivascular endothelial growth factor injectionsAntivascular endothelial growth factor injectionsCases of RVOEndothelial growth factor injectionsGrowth factor injectionsChoice of treatmentMulticenter collaborative studyEdema studyFactor injectionsNonsurgical treatmentNumber of treatmentsVEGF injectionPlana vitrectomyRVO casesILM peelingRetina specialistsVisual gainDiagnostic findingsVisual improvement
2014
Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal Of Ocular Pharmacology And Therapeutics 2014, 30: 346-352. PMID: 24552305, DOI: 10.1089/jop.2013.0188.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansIntravitreal InjectionsMacular DegenerationMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityConceptsAge-related macular degenerationCentral macular thicknessAflibercept injectionsInitial visitMacular degenerationAnti-vascular endothelial growth factor treatmentNeovascular age-related macular degenerationEndothelial growth factor treatmentCentral macular edemaIntraocular pressure increaseSubset of patientsMain outcome measuresOptical coherence tomographyGrowth factor treatmentMacular thicknessNeovascular AgeOcular hypertensionSubmacular fluidVisual outcomeMacular edemaRetrospective studyVisual acuityOutcome measuresStudy populationPatients
2013
Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents
Abedi G, Adelman RA, Salim S. Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents. Seminars In Ophthalmology 2013, 28: 126-130. PMID: 23631423, DOI: 10.3109/08820538.2013.771195.Peer-Reviewed Original ResearchConceptsPersistent ocular hypertensionIntraocular pressureOcular hypertensionIntravitreal antivascular endothelial growth factorAntivascular endothelial growth factor agentsChronic intraocular pressure elevationEndothelial growth factor agentsIntravitreal anti-VEGF injectionsAntivascular endothelial growth factorAnti-VEGF injectionsGrowth factor agentsIntraocular pressure elevationElevated intraocular pressureElectronic literature searchEndothelial growth factorKey search termsFactor agentsPrompt diagnosisVEGF injectionAcute elevationIntravitreal injectionIOP elevationPersistent elevationPressure elevationGlaucomatous eyes
2012
Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy?
Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy? Journal Of Neuro-Ophthalmology 2012, 32: 51-53. PMID: 22269947, DOI: 10.1097/wno.0b013e318240596e.Peer-Reviewed Original ResearchConceptsNonarteritic anterior ischemic optic neuropathyAnterior ischemic optic neuropathyIschemic optic neuropathyVisual acuityIntravitreal bevacizumabOptic neuropathyTreatment optionsIntravitreal bevacizumab injectionEffective treatment optionVisual field defectsBevacizumab injectionFellow eyesClinical outcomesRetrospective studyTreatment modalitiesNatural courseField defectsPatientsDecreased acuitySmall seriesAcuityBevacizumabProfound lossVisual fieldNeuropathy
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy
2009
Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions
Peng S, Adelman RA, Rizzolo LJ. Minimal Effects of VEGF and Anti-VEGF Drugs on the Permeability or Selectivity of RPE Tight Junctions. Investigative Ophthalmology & Visual Science 2009, 51: 3216-3225. PMID: 20042644, PMCID: PMC2891474, DOI: 10.1167/iovs.09-4162.Peer-Reviewed Original ResearchAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabBlood-Retinal BarrierCapillary PermeabilityCells, CulturedClaudinsElectric ImpedanceEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectGene ExpressionHumansImmunoblottingPolyethylene GlycolsPotassiumRanibizumabRetinal Pigment EpitheliumReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSodiumTight JunctionsVascular Endothelial Growth Factor A
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
2007
Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis
Seth RK, Stoessel KM, Adelman RA. Choroidal Neovascularization Associated with West Nile Virus Chorioretinitis. Seminars In Ophthalmology 2007, 22: 81-84. PMID: 17564926, DOI: 10.1080/08820530701418375.Peer-Reviewed Original ResearchConceptsWest Nile virus chorioretinitisChoroidal neovascularizationChoroidal Neovascularization AssociatedLate-onset complicationsBest therapeutic optionGood anatomical responseNeovascularization AssociatedDiabetes mellitusLeft eyeIntravitreal injectionTherapeutic optionsChorioretinitisNeovascularizationBevacizumabPatientsInjectionMellitusComplicationsBaseline